A Comparison of 141W94 and Indinavir in HIV-Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Indinavir sulfate

DRUG

Amprenavir

Trial Locations (24)

10001

Community Research Initiative on AIDS, New York

10027

Harlem Hosp, New York

20009

Whitman Walker Clinic Inc, Washington D.C.

23666

Hampton Roads Med Specialists, Hampton

28207

The Nalle Clinic / Clinical Research Dept, Charlotte

32751

Community Research Initiative of Central Florida, Maitland

33136

Univ of Miami Dept of Medicine, Miami

33146

CRI of South Florida, Coral Gables

38104

Methodist Hosp, Memphis

43614

Med College of Ohio / Division of Infectious Diseases, Toledo

60611

Northwestern Univ Med School, Chicago

70112

Tulane Univ Med School, New Orleans

75217

Community Oriented Primary Care, Dallas

80262

Univ of Colorado Health Sciences Ctr, Denver

90027

AIDS Healthcare Foundation, Los Angeles

94109

Saint Francis Mem Hosp, San Francisco

ViRx Inc, San Francisco

94705

East Bay AIDS Ctr, Berkeley

97210

The Research and Education Group, Portland

681985400

Univ of Nebraska Med Ctr, Omaha

770303498

Baylor College of Medicine / Dept of Medicine, Houston

775550835

Univ of Texas Med Branch, Galveston

021182393

Boston Med Ctr / Evans - 556, Boston

02215

Beth Israel Deaconess Med Ctr, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002202 - A Comparison of 141W94 and Indinavir in HIV-Infected Patients | Biotech Hunter | Biotech Hunter